SG10201403138WA - Novel 2,3-dihydro-1h-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof and pharmaceutical use thereof - Google Patents

Novel 2,3-dihydro-1h-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof and pharmaceutical use thereof

Info

Publication number
SG10201403138WA
SG10201403138WA SG10201403138WA SG10201403138WA SG10201403138WA SG 10201403138W A SG10201403138W A SG 10201403138WA SG 10201403138W A SG10201403138W A SG 10201403138WA SG 10201403138W A SG10201403138W A SG 10201403138WA SG 10201403138W A SG10201403138W A SG 10201403138WA
Authority
SG
Singapore
Prior art keywords
imidazo
pyrimidin
dihydro
derivatives
novel
Prior art date
Application number
SG10201403138WA
Other languages
English (en)
Inventor
Maurice Brollo
Annie Clauss
Ahmad Youssef El
Bruno Filoche-Romme
Frank Halley
Karl Andreas Karlsson
Gilbert Marciniak
Baptiste Ronan
Laurent Schio
Bertrand Vivet
Fabrice Viviani
André Zimmermann
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0903236A external-priority patent/FR2947550B1/fr
Priority claimed from FR0957067A external-priority patent/FR2951173B1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG10201403138WA publication Critical patent/SG10201403138WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG10201403138WA 2009-07-02 2010-07-01 Novel 2,3-dihydro-1h-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof and pharmaceutical use thereof SG10201403138WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0903236A FR2947550B1 (fr) 2009-07-02 2009-07-02 Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
US24109709P 2009-09-10 2009-09-10
FR0957067A FR2951173B1 (fr) 2009-10-09 2009-10-09 Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)

Publications (1)

Publication Number Publication Date
SG10201403138WA true SG10201403138WA (en) 2014-08-28

Family

ID=43127464

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2011097227A SG177421A1 (en) 2009-07-02 2010-07-01 Novel 2,3-dihydro-1h-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof
SG10201403138WA SG10201403138WA (en) 2009-07-02 2010-07-01 Novel 2,3-dihydro-1h-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof and pharmaceutical use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2011097227A SG177421A1 (en) 2009-07-02 2010-07-01 Novel 2,3-dihydro-1h-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof

Country Status (25)

Country Link
US (1) US8828997B2 (de)
EP (1) EP2448939B1 (de)
JP (1) JP5663571B2 (de)
KR (1) KR101745028B1 (de)
CN (1) CN102482285B (de)
AR (1) AR077446A1 (de)
AU (1) AU2010267814B2 (de)
BR (1) BRPI1015949A2 (de)
CA (1) CA2767051C (de)
CY (1) CY1119442T1 (de)
DK (1) DK2448939T3 (de)
ES (1) ES2627428T3 (de)
HR (1) HRP20170827T1 (de)
HU (1) HUE034503T2 (de)
IL (1) IL217294A (de)
LT (1) LT2448939T (de)
MX (1) MX2012000097A (de)
PL (1) PL2448939T3 (de)
PT (1) PT2448939T (de)
RU (1) RU2554868C2 (de)
SG (2) SG177421A1 (de)
SI (1) SI2448939T1 (de)
TW (1) TWI458730B (de)
UY (1) UY32753A (de)
WO (1) WO2011001112A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815853B2 (en) 2010-12-23 2014-08-26 Sanofi Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof
FR2969612B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
AU2012354094C1 (en) 2011-12-15 2015-10-15 Novartis Ag Use of inhibitors of the activity or function of PI3K
FR2992314B1 (fr) * 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
FR2992316A1 (fr) * 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique
KR102572178B1 (ko) * 2015-01-23 2023-08-28 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 피라졸로[3,4-d]피리미딘 유도체 및 리슈마니아증의 치료를 위한 그의 용도
RU2734877C2 (ru) * 2015-08-07 2020-10-23 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения
JP2019086340A (ja) * 2017-11-02 2019-06-06 シスメックス株式会社 細胞検出方法および細胞検出システム
WO2022093820A1 (en) * 2020-10-28 2022-05-05 Genentech, Inc. Substituted morpholine compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5888381A (ja) * 1981-11-24 1983-05-26 Ube Ind Ltd イミダゾピリミジン類
US20020077327A1 (en) * 1999-09-23 2002-06-20 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
NZ520300A (en) 2000-01-24 2004-05-28 Kinacia Pty Ltd Morpholino-substituted pyridopyrimidine, quinolone and benzopyranone derivatives that inhibit the enzyme phosphoinositide (PI) 3-kinase
EP1184384A1 (de) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 1-Alkyl, 1-(Heteroaryl)alkyl und 1-(Aryl)alkyl-7-pyridin-4-ylimidazo[1,2-a]pyrimidin-5(1H)-on Derivate
TR200402342T4 (tr) * 2000-09-01 2004-11-22 Mitsubishi Pharma Corporation 2-Pirindinil-6,7,8,9- Tetrahidropyrimido[1,2-A] Pirimidin-4-On ve 7-Pirindinil-1,3-Dihydoimidazo[1,2-A]Pirimidin-5(1H) on Türevleri
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
EP1340761A1 (de) 2002-02-28 2003-09-03 Sanofi-Synthelabo Substituierte 2-Pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on und 7-Pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivate
CN1247585C (zh) 2001-09-21 2006-03-29 赛诺菲安万特 取代的2-吡啶基-6,7,8,9-四氢嘧啶并[1,2-a]嘧啶-4-酮及7-吡啶基-2,3-二氢咪唑并[1,2-a]嘧啶-5(1h)酮衍生物
NZ534466A (en) * 2002-02-28 2006-04-28 Sanofi Aventis Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl - 6,7,8,9- tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
EP1340759A1 (de) * 2002-02-28 2003-09-03 Sanofi-Synthelabo 1-Alkyl, 1-(Heteroaryl)alkyl und 1-(Aryl)alkyl-7-pyrimidin-4-ylimidazo[1,2-a]pyrimidin-5(1H)-on Derivate
US7598377B2 (en) 2002-08-16 2009-10-06 Astrazeneca Ab Inhibition of phosphoinositide 3-kinase β
CN1898243A (zh) * 2003-12-23 2007-01-17 诺瓦提斯公司 二环杂环类p-38激酶抑制剂
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
WO2006126010A2 (en) * 2005-05-26 2006-11-30 Kudos Pharmaceuticals Limited Use of dna-pk inhibition to sensitise atm deficient cancers to dna-damaging cancer therapies
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
WO2008148074A2 (en) 2007-05-24 2008-12-04 Research Foundation Of State University Of New York Inhibitors of mtor and methods of treatment using same

Also Published As

Publication number Publication date
HRP20170827T1 (hr) 2017-08-25
PT2448939T (pt) 2017-06-12
SG177421A1 (en) 2012-02-28
JP5663571B2 (ja) 2015-02-04
IL217294A0 (en) 2012-02-29
IL217294A (en) 2015-07-30
LT2448939T (lt) 2017-06-12
CN102482285A (zh) 2012-05-30
CA2767051A1 (fr) 2011-01-06
US20120142679A1 (en) 2012-06-07
SI2448939T1 (sl) 2017-06-30
KR20120103552A (ko) 2012-09-19
CY1119442T1 (el) 2018-03-07
CN102482285B (zh) 2015-07-15
AR077446A1 (es) 2011-08-31
EP2448939A1 (de) 2012-05-09
WO2011001112A1 (fr) 2011-01-06
DK2448939T3 (en) 2017-06-19
US8828997B2 (en) 2014-09-09
RU2012103460A (ru) 2013-08-10
CA2767051C (fr) 2017-08-22
HUE034503T2 (en) 2018-02-28
UY32753A (es) 2011-01-31
TWI458730B (zh) 2014-11-01
EP2448939B1 (de) 2017-03-01
MX2012000097A (es) 2012-02-28
AU2010267814A1 (en) 2012-02-16
KR101745028B1 (ko) 2017-06-08
AU2010267814B2 (en) 2015-07-16
TW201105672A (en) 2011-02-16
JP2012531462A (ja) 2012-12-10
BRPI1015949A2 (pt) 2016-04-26
RU2554868C2 (ru) 2015-06-27
ES2627428T3 (es) 2017-07-28
PL2448939T3 (pl) 2017-08-31

Similar Documents

Publication Publication Date Title
HK1253364B (zh) 1h-吡唑並[3,4-b]吡啶及其治療應用
IL215911A (en) 7-aryl-1,2,4-triazolo [3,4- a] derivatives, pharmaceutical preparations containing them and methods of preparation and uses thereof
SG10201403138WA (en) Novel 2,3-dihydro-1h-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof and pharmaceutical use thereof
SI2069342T1 (sl) Derivati aril fenil imidazo a piridinov njihova priprava in njihova terapevtska uporaba
IL213993A (en) History of 4,3,2,1-tetrahydropyrido [3,2-b] pyrazine-2-one and pharmaceutical preparations containing them
IL200695A (en) History of Hydro-Oxazolo [2,3-a] Pyrimidine-7-Wen and Pharmaceutical Preparations Containing Them
IL215644A (en) N-phenylsulfonyl-2- (h1-pyrrolo [3,2- b] pyridine-5-yloxy) benzamide and anticancer drugs containing them
HK1169388A1 (en) 6,7,8,9-tetrahydro-pyrimido1,2-a pyrimidin-4-one derivatives, their preparation and pharmaceutical use thereof 6789-12-a -4-
IL220432A (en) History of theo [b – 3,2] pyridinedione and pharmaceutical preparations containing them
IL236170A0 (en) 2,3-dihydro-h1-imidazo[a-1,2]pyrimidin-5-one and 1,2,3,4-tetrahydropyrimido[a-1,2]pyrimidin-6-one derivatives containing modified morpholine, their preparation and pharmaceutical use their
IL206673A0 (en) Imidazo[1,2-a]pyridine-2-carboxamide derivatives, their preparation and their therapeutic application
IL212942A (en) History of Rifamycin, Methods of Preparation, Pharmaceutical Preparations Containing Them and Their Uses
SI1902054T1 (sl) Derivati pirido(2,3-d)pirimidina, njihova priprava, njihova terapevtska uporaba
IL223364A (en) Derivatives of 4,3-Dihydro-pyrrolo [2,1-a] pyrene 2,8 (1 h) - dicarboxamide, their preparation, and their medical use
IL206671A0 (en) N-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
IL220448A (en) Pyridine [3,2 - d] Pyrimidine - 7 (8h) - Their medical uses and uses
IL206669A0 (en) 6-HETEROCYCLIC IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
EP2578586A4 (de) Hexahydropyrrolo-[3,4-b-]pyrrol-derivate, herstellungsverfahren dafür und pharmazeutische anwendungen davon
IL206672A0 (en) N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
IL215733A0 (en) 1-pyrazolo[4,3-c]isoquinoline derivatives, preparation thereof and therapeutic use thereof
IL206665A0 (en) 2-BENZOYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
IL206667A0 (en) 2-HETEROAROYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
IL213380A (en) Morphine-6-glucuronide bicarbonate derivatives, containing pharmaceutical preparations and their use in the preparation of drugs
HUP1000034A2 (en) Pyrido[1,2-a]pyrimidine derivatives and pharmaceutical preparations thereof having anti - mycobacterial activity